("Onco" or the "Company") is pleased to provide information regarding its second-generation nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) Compound (the "Technology") in ...

for the custom synthesis of a heavy labelled isotope of its exclusively-licensed Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor (the "Technology"), based on a nanoparticle formulation of ...

for the custom synthesis of a heavy labelled isotope of its exclusively-licensed Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitor (the "Technology"), based on a nanoparticle formulation of second ...

Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H ,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to provide information on its exclusive-licensed technology, a new class of Polynucleotide Kinase 3' ...

Pancreatic cancer is a leading cause of cancer-related death, with a five-year survival rate of 13%. The high mortality is ...

You're not likely to hear it brought up in casual conversation, but recombinant DNA has changed the world in a relatively short period of time.

Kinases represent highly tractable drug targets, with kinase inhibitors achieving significant success, particularly in oncology. However, their potential in neurodegenerative diseases remains largely ...